BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DBV Technologies Proudly Welcomes Mrs. Veronique Foutel as Chief Strategic Marketing Officer


6/6/2013 10:59:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BAGNEUX, FRANCE--(Marketwired - June 06, 2013) -

DBV Technologies (EURONEXT PARIS: DBV) (ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Véronique Foutel as Chief Strategic Marketing Officer. In this position and in full partnership with the other members of the DBV leadership team, Véronique will be accountable for developing a sustainable market access strategy and business model for DBV's products currently under development.

Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies said: "The medical needs in food allergies are immense and DBV is well positioned to fulfill these urgent needs. Crafting the commercialization strategy is clearly DBV's next challenge. Véronique's knowledge of the pharma market coupled with her broad business experience around the globe will be key at this stage while we are moving closer to commercialization. I am proud to welcome Véronique, a seasoned professional bringing to the team considerable expertise in market access and planning strategies. Veronique is a perfect addition to the team, and shares our passion for Viaskin, a unique technology that could change the life of millions of patients suffering from food allergies."

Véronique gained an extensive experience of almost two decades in drug asset value identification, evaluation, creation, dissemination and confirmation through the tenure of diverse and complementary roles initially held within the French Health Authorities and later on in the Pharma Industry, mainly in the Pharma Division of Roche between 1996 and 2012 in Western Europe, in North America and at its Headquarters in Switzerland. For the past nineteen years, Véronique has actively contributed to the positioning, the market entry, the market maintenance as well as the licensing of numerous drug assets across many therapeutic areas at any development and/or commercial stages, some of these products having been acknowledged as ground breaking therapies and enjoying a blockbuster status. Véronique holds a doctorate in Pharmaceutical Sciences from the University Paris V Descartes and is a former hospital resident of Assistance Publique- Hôpitaux de Paris.

About DBV Technologies:

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies -- a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people, constituting a major unmet medical need. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanuts, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure The product's clinically proven safety profile enables the application of effective desensitization techniques in the most severe forms of the allergy.
DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration and is currently being studies in Phase II program. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy -- a true public health issue because this pathology is a primary risk factors for childhood asthma.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Mrs. Veronique Foutel as Chief Strategic Marketing Officer: http://hugin.info/156437/R/1707479/565440.pdf


Contacts

DBV Technologies
David Schilansky
Chief Financial Officer
Tel. : +33(0)1 55 42 78 75
david.schilansky@dbv-technologies.com

US & UK investors
The Trout Group
Investor Relations
Alan S. Roemer
Tel. : +1 (212) 531-3315
aroemer@troutgroup.com

French investors
NewCap.
Financial Communication and investor relations
Emmanuel Huynh / Valentine Brouchot
Tel. : +33(0)1 44 71 94 94
dbv@newcap.fr

US press & media
Ronald Trahan
APR
Press relations
Ronald Trahan
Tel. : +1 508 359 4005
rctrahan@ronaldtrahan.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES